Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso Sells 36,838 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the completion of the transaction, the chief executive officer now owns 107,087 shares in the company, valued at $500,096.29. The trade was a 25.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 4th, Michael Amoroso sold 3,012 shares of Precision BioSciences stock. The shares were sold at an average price of $8.19, for a total value of $24,668.28.

Precision BioSciences Price Performance

NASDAQ:DTIL opened at $5.08 on Friday. The company has a market capitalization of $38.96 million, a P/E ratio of 84.68 and a beta of 1.51. The business’s 50-day moving average is $5.46 and its 200 day moving average is $7.96. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a 12 month low of $3.61 and a 12 month high of $19.43.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DTIL shares. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research note on Friday, January 10th.

Institutional Trading of Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC increased its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 65,974 shares of the company’s stock after purchasing an additional 19,088 shares during the period. Geode Capital Management LLC owned approximately 0.86% of Precision BioSciences worth $591,000 at the end of the most recent quarter. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.